On April 28, 2025 Vector Laboratories, a manufacturing partner of reagents and critical components for the development and production of life sciences tools, diagnostics, and clinical-stage biotherapeutics, in partnership with Spatomics, which specializes in developing spatial biology research tools, reported a poster at AACR (Free AACR Whitepaper) detailing a highly sensitive, multiplexed single-cell in situ analysis method that enables simultaneous detection of ten or more protein and glycan targets in the same biological sample (Press release, Vector Laboratories, APR 28, 2025, View Source [SID1234652282]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The poster, "Multiplexed spatial profiling of protein and glycan expression using CFP fluor cleavable TSA fluorophores," was authored by scientists at Spatomics and Vector Laboratories. It describes a novel platform integrating off-the-shelf antibodies and lectins for sensitive multiplexed detection, opening up new insights into complex biological systems.
Spatomics employs a multiplexing strategy centered around its patented Cleavable Fluorescent Probe (CFP) fluorophores, which allows reiterative cycles of staining, imaging, and fluorophore cleaving. This enables sensitive, high-multiplex imaging without the use of highly complex or specialized detection systems.
"This partnership demonstrates our commitment to continue to improve the tools available for crucial basic research," said Lisa V. Sellers, PhD, CEO of Vector Laboratories. "We’re proud that this approach enables the multiplexed detection of in-situ glycosylation using Vector’s lectins, which have been validated over the years by the National Center for Functional Glycomics. We look forward to ultimately applying this approach to other research areas, including cancer biology, immunology, neuroscience, and infectious disease."
"We are excited to join with Vector Laboratories to bring this research to the attention of the scientific community," said Dr. Rui Zheng, CEO of Spatomics. "Our CFP Cleavable TSA fluorophore is the only commercially available fluorophore that leverages tyramide signal amplification and enables efficient removal of the fluorescent signal after staining."
The collaboration between Vector Laboratories and Spatomics will serve basic research in three key ways:
by making comprehensive multiplexing accessible to scientists;
by addressing biology questions in specific research areas where they are most effective;
by developing biomarker signatures that help in understanding disease state versus normal and could also facilitate target identification.
The poster will be presented at AACR (Free AACR Whitepaper) this afternoon, Central Time: Poster Section 52; Poster Board Number 17. The session title is "Late-Breaking Research: Chemistry." Authors of the poster are Nishinki Muthumuni, Jia Guo, Dana Ashworth, Rui Zheng, Jing Zhou, Shuhui Chen, Erika Leonard, Shamali Roy, and Xiaoshan Wang.
In 2024, Vector Laboratories merged with Absolute Biotech, expanding its manufacturing and distribution footprint from multiple manufacturing sites in the US to the UK and Europe. Absolute Biotech serves customers globally with antibody reagents, kits, and services to provide annotation, validation, sequencing, engineering, and recombinant manufacturing.